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ABSTRACT   
Background 
There is limited information on gender differences in patients with Brugada syndrome 
(BrS) who experienced arrhythmic events (AEs).  
Objectives 
To compare clinical, electrocardiographic (ECG), electrophysiologic (EP) and genetic 
characteristics between males and females in BrS-patients with their first AE. 
Methods 
The multicenter Survey on AE in BrS (SABRUS) collected data on first AE in 678 BrS-
patients including 619 (91.3%) males and 59 (8.7%) females aged 0.27 to 84 (mean 
42.5±14.1) years at the time of AE. 
Results 
After excluding pediatric patients, females were older than males (49.5±14.4 vs. 43±12.7 
years, respectively, P=0.001). Higher proportions of females were observed in the 
pediatric and elderly populations. In Asians, male/female ratio of AE was ≈9-fold higher 
compared to Caucasians. Spontaneous type 1 BrS-ECG was associated with earlier onset 
of AE in pediatric females. A similar prevalence (≈65%) of spontaneous type 1 BrS-ECG 
was present in males and females above age of 60 years. 
Females less frequently showed a spontaneous type-1 BrS-ECG (31% vs. 59%, P<0.001) 
or arrhythmia-inducibility at EP study (34% vs. 64%, P<0.001). An SCN5A mutation was 
more frequently found in females (47.6% vs. 27.8% in males, P=0.007).  
Conclusions 
This study confirms that female BrS-patients are much rarer, display less type 1 
Brugada-ECG and exhibit lower inducibility rates than males. It shows for the first time 
that BrS females with AE have higher SCN5A mutation rates as well as the relationship 
between gender vs. age at onset of AE and ethnicity. 
 
  
 
Keywords: Sudden cardiac death; SCN5A mutation; Ethnicity; Implantable cardioverter 
defibrillator; Brugada-ECG.  
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Brugada syndrome (BrS) is an inherited arrhythmic disorder that exposes patients with 
ostensibly normal hearts to sudden cardiac death (SCD).
1
 Although the mode of 
inheritance has been recently questioned 
2
 , symptomatic BrS is surprisingly uncommon 
in females. The largest series include only 7-9 females with aborted cardiac arrest (CA) 
3,4
 and up to 4 females with AE after prophylactic ICD-implantation or follow-up of BrS-
patients without ICD.
5-8
  
We recently reported the results of a multicenter international survey on AE in BrS 
(SABRUS) on a large cohort of 678 BrS-patients with their first ever documented AE, 
including 59 females.
 9,10
  
The present study sought to compare males and females in the SABRUS patient 
population. 
 
METHODS 
CENTER SELECTION AND PATIENT RECRUITMENT   
As detailed elsewhere
9
 a total of 678 BrS-patients were recruited from 23 centers 
worldwide. These centers were located in 10 Western (415 patients, 61.2%) and 4 Asian 
countries (263 patients, 38.8%) and provided 7 to 105 patients per center. Sixteen 
centers (69.5%) reported their sole experience and 7 (31.5%) collected the experience of 
multiple institutions. All centers except two, declared no age limitation at patient 
recruitment. 
The study was approved by the Research Ethics Boards of all participating institutions. 
DATA ACQUISITION. 
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Anonymous patient information was retrospectively collected using a predefined 
questionnaire regarding the following: 1) gender; 2) age at the time of the first AE; 3) 
mode of AE documentation (Group A or Group B, see below); 4) ethnicity (Caucasian, 
Asian, other or unknown); 5) proband status; 6) family history of SCD;  7) prior history of 
syncope ; 8) presence of spontaneous or drug-induced Brugada-ECG type 1; 7) 
inducibility of sustained ventricular fibrillation (VF) at EP study (EPS) and 9) results of 
genetic testing for the presence of SCN5A mutation. 
In addition all 23 SABRUS centers were requested to provide the gender and age 
distribution of the entire BrS-population followed at their own centers (with or without 
prior AE).  The centers from Western and Asian countries were assumed to include 
Caucasian and Asian patients, respectively, based on initial SABRUS results.
9
     
DEFINITIONS. 
Arrhythmic events: Defined as any sustained ventricular tachyarrhythmia documented 
during initial aborted CA (group A) or triggering ICD-shock therapy after prophylactic 
implantation of an ICD (group B).  
Age cut-offs: The rationale for using age cut-offs of 16 years for the pediatric patients 
and 70 years for the elderly has been explained elsewhere.
9
   
Patient groups according to indication for ICD-implantation: Group B patients were 
subdivided by their indication for a prophylactic ICD-implantation as stated in the 2013 
Expert Consensus Statement:
11
 
- Group B1: Class IIa indication. 
- Group B2: Class IIb indication. 
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- Group B3: Implanted with an ICD that subsequently proved to be justified (i.e. 
triggering appropriate ICD-shock therapy for AE) despite not complying with the above 
indications. These patients were further divided into 2 subgroups according to the EPS 
results: a) Group B3a: no arrhythmias inducible at EPS; b) Group B3b:  EPS was not 
performed. 
STATISTICAL ANALYSIS.  
Differences between ages of different groups were assessed using a Mann–Whitney U 
test. Ratio differences were examined by a Chi-square test or a Fisher's exact test as 
appropriate. Scale variables are presented as mean±SD and nominal variables as N 
(Percentage). Statistical significance was defined as P<0.05. All calculations were 
performed using SPSS version 24 (IBM, Armonk, NY, USA).                                                           
 
                                                               RESULTS 
The demographic, clinical, ECG, EPS and genetic findings of the patients in respect to 
gender are presented in Table 1. 
Demographics. Out of 678 patients included in SABRUS, aged 0.27 to 84 years old, 619 
were male (91.3%) and 59 (8.7%) were female. The vast majority (94.2%) of patients 
were 16 to 70 years old.   
Gender distribution. The male to female (M/F) ratio was 10.4 for the whole group ranging  
from 25.2 in the 27-37 age group to 1.9 and 2.0 in the pediatric and elderly groups, 
respectively (Figure 1A). The proportion of females was highest among the pediatric (17% vs. 
3% of males, P<0.001) and the elderly groups (5% vs. 1% of males, P<0.05) while that of males 
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was highest between ages 16-70 years (96% vs. 78% of females, P<0.001) (Table 1). In the 
pediatric group (n=29), there was a similar proportion of males and females in the 6-15 years 
group (42 and 40%, respectively) and in infants <5 years (58 and 60%, respectively). One of 
the 2 oldest study patients aged 84 years old was a female. 
Age at time of AE. In the whole study-population the age at the time of the AE was not-
normal distributed with no significant difference between males (41.9±14.0 years, 
Median [IQR] 42.0 [33.0-52.0]) and females (42.1±21.2 years, Median [IQR] 46.0 [28.0-
58.0] ) (P=0.225) (Tables 1 and 2A). Excluding the pediatric-patients from the entire 
cohort resulted in a normal age distribution with females being significantly older than 
males (49.5±14.4 vs. 43±12.7 years respectively, P=0.001) (Table 2B). Similar gender 
related differences in age were observed in several subgroups in patients aged >16 
years (Table 2B). In the pediatric group the ages of males and females at the time of AE 
were similar (6.2±4.9 and 5.8±6.2 years, respectively, P=0.636) (Table 2C); however, the 
presence of spontaneous type-1 BrS-ECG was associated with earlier onset of AE in the 
pediatric group in females as compared to males (Table 2C).  
Mode of AE documentation. There was no gender difference in the proportion of 
patients belonging to groups A and B. There were similar rates of males (63%) and 
females (61%) in group A (Table 1).  
Ethnicity. Compared to males, females were more frequently Caucasian (88% vs. 50%) 
and markedly less frequently of Asian origin (8% vs. 43%) (P<0.001). The M/F ratio was 
higher in Asians than in Caucasians (53 vs. 6) (Table 1) with a peak-ratio in the 38-48 
year age-group for Asians and in the 27-37 year age-group for Caucasians (Figure 2A). Of 
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note, in the pediatric group, 25 of 26 patients with known ethnicity were Caucasian (16 
males and 9 females) while there was a single Asian male. In the elderly group, 7 were 
Caucasian (4 males and 3 females) and the 2 Asians were male.  
Proband status. Of the 678 study-patients 542 (496 males) were probands and 88 (76 
males) were diagnosed during family screening. The proportions of probands in 
Caucasians and Asians were 83.5 and 91.5%, respectively, with no significant gender 
difference between the various age groups. (Online Figure).  
Clinical history. A family history of SCD was noted in a similar proportion of patients of 
females (29%) and males (21%) (P=0.287) (Table 1). The 3 highest proportions of family 
history of SCD (40-50%) were noted in females (Figure 3A). A prior history of syncope 
was also noted in a higher proportion of females (47%) than males (38%) but the 
difference did not reach statistical significance (P=0.168) (Table 1, Figure 3B).   
ECG. A spontaneous type-1 BrS-ECG was significantly more frequently observed in males 
(69%) than females (41%) (P<0.001) (Table 1). This difference was maintained up to 59 
years of age at time of AE (Figure 3C); after age 60 years, a similar high incidence (≈65%) 
of spontaneous type-1 BrS-ECG was observed in both genders.  
EPS. EPS was performed in a similar proportion of females and males (66% and 58%, 
respectively, P=0.246). The rate of VF-induction was significantly lower in females (36% 
vs. 66%, P<0.001) (Table 1) regardless of the patient’s age at the AE (Figure 3D). 
Genetic testing. Genetic testing was performed in a similar proportion of female and 
male patients (71% and 72%, respectively). In the whole patient group, an SCN5A 
mutation was found more frequently in females (47.6% vs. 27.8% in males, P=0.007) 
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(Table 1). However, in patients aged <16 years, mutation rates were similarly high (70% 
and 66.7% in females and males, respectively, P=0.86) whereas in patients >16 years, 
there was only a trend toward higher mutation rates in females (40.6% vs. 26.4%, 
P=0.082) (Table 3, Figure 4). Both males and females had most of their mutations 
classified as pathogenic or likely pathogenic (89.9% vs. 78.9%, respectively) with no 
significant difference between genders (P=0.237).  
Online Table 1 shows the main demographic, clinical, ECG and EP differences between 
443 males and 42 females who underwent genetic testing in respect to the presence of 
an SCN5A mutation.  
Data from the registry. Data on patient gender and age distribution were provided by 22 of 
the 23 SABRUS centers.  Of note, only 5 of these 22 main centers were from Asian countries 
while the majority was from Western countries. The registry comprised 6441 patients (73.4% 
males and 26.6% females) (Online Table 2).  The involvement of Asian patients was very low 
at high and low ends of the age spectrum (1% and 2% for the pediatric group and the elderly 
groups, respectively) while it ranged between 7.8 to 12.9% in the other age groups. The M/F 
ratios were the highest (3.8-3.9) in the 27-48 year age-group and the lowest at the pediatric 
and elderly age groups (1.2 and 1.8, respectively) (Figure 1B). In Western countries the M/F 
ratio ranged from 1 in both the pediatric and elderly groups to 3 in the 27-48 year age group. 
In Asian patients it ranged from 10 in the 49-59 year age-group to 86 in the 27-37 year age-
group (Figure 2B).  
Indications of prophylactic ICD-implantation. There was no difference between the 
proportions of males (37%) and females (39%) who underwent prophylactic ICD-
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implantation (Group B).  A higher proportion of females (8 of 23, 35% vs. 55 of 229, 24% 
of males) belonged to Group B3 (Table 1); however, this difference did not reach 
statistical significance (P=0.25).  
 
                                                                  DISCUSSION  
The present study compares the clinical, ECG, EP and genetic characteristics of 619 male 
and 59 female BrS-patients with a first documented AE. The prior largest comparative 
study by Sacher et al
5
 involved 11 European centers comprised 50 males (33 with 
aborted CA) and only 8 females (3 with aborted CA).  
CONFIRMATORY STUDY RESULTS. 
The results of our study confirmed several known characteristics of the female 
gender:
5,7,8
  
Rarity of AE in BrS females. Our results confirm the rare occurrence of AE in female BrS-
patients (M/F ratio of 10.4 in the survey) despite the non-negligible prevalence of the 
disease in that population (M/F ratio of 2.75 in the registry). Sieira et al.
8
 reported on 
the highest AE-rate in females (6 of 23, 26%) in a series of 542 BrS-patients (42% 
females). They explained their large female cohort by a proactive search of BrS and an 
exhaustive familial screening program performed at their institution. 
Lower prevalence of spontaneous type 1 Brugada-ECG.  Out of a population of 58 
patients with AE, Sacher et al.
5
 found a spontaneous type-1 BrS-ECG at baseline in 36 
men (72%) but in only 2 women (25%) (P=0.02). Sieira et al.
5
 also found a low incidence 
rate (1 of 7, 14%) of spontaneous type-1 BrS-ECGs in females with AE. In contrast, in 
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PRELUDE
6
 all 3 BrS-females who exhibited an AE after prophylactic ICD-implantation had 
spontaneous type-1 BrS-ECGs. In SABRUS a spontaneous type-1 BrS-pattern was 
observed in 69% of males and 41% of females with AE (P<0.001). Although our results 
confirm the lower female prevalence of spontaneous type-1 BrS-ECGs, the relatively 
high figure of 41% in females has never been reported previously.  
Lower VF-inducibility rate.  The lower VF-inducibility rate in BrS-females has been 
previously observed in all clinical settings of BrS.
5,7,8
 In SABRUS, a similar lower 
percentage of VF-inducibility was observed in females (36% vs. 66% in males, P<0.001).  
NEW STUDY FINDINGS.                                                                                                               
Gender and age at onset of AE. Our study showed that gender distribution markedly 
varied in respect to patient age group at time of AE with a higher proportion of females 
among the pediatric and elderly age groups contrasting with a higher proportion of 
males between ages 16-70 years. Similar results were observed in the SABRUS-registry.  
Gender and ethnicity. SABRUS also showed for the first time that gender distribution of 
AE was markedly dependent on patient ethnicity. The M/F ratio of AE in Asians was ≈9 
fold higher than in Caucasians. Interestingly, analyzing the registry of the 22 main 
SABRUS centers showed a similar M/F risk ratio of 8 with M/F ratios of 19.2 and 2.4 in 
Asians and Caucasians, respectively. An electrophysiological mechanistic explanation of 
the extremely high M/F ratio in Asians compared to Caucasians may be due to the 
presence of modifier genes in Asians but not in Caucasians (12).   
Earlier onset of AE in pediatric females. We found that the presence of spontaneous 
type-1 BrS-ECG’s was associated with an earlier onset of AE in the pediatric group in 
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females as compared to males (Table 2C). This finding suggests that in the pediatric 
population, a spontaneous type-1 BrS-ECG in females might represent a significant 
arrhythmic risk marker. 
Prevalence of spontaneous type-1 BrS-ECG.  Contrasting with the higher prevalence of 
spontaneous type-1 BrS-ECG in males before age 60, a similar prevalence (≈65%) of 
spontaneous type-1 BrS-ECG was present in males and females above the age of 60 
years (Figure 3C). This suggests that ageing is a relevant contributor to the development 
of a type-1 ECG, which could relate to an age-related development of (ultra)structural 
abnormalities, that has previously been shown in SCN5A-knockout mice.
13
  
Gender and presence of SCN5A gene mutations. The most interesting finding in our 
present study relates to major gender differences in genetic characteristics. A recent 
Japanese study involving 97% of males showed that SCN5A mutation was a significant 
predictor of cardiac events in BrS probands.
14
 In our study which involved 91.3% of 
males and 79.9% of probands, an SCN5A mutation was found more frequently in 
females (47.6%) than in males (27.8%) (P=0.007). Interestingly this was observed in all 
age groups at time of AE (Figure 4). Of note, when subdividing the population to above 
or below 16 years old, no difference in mutation rate was seen in the pediatric 
population and only a trend towards statistical significance was seen in adults probably 
due to relative small size of the female SABRUS group. Also, in our male SABRUS-
patients the SCN5A mutation rate was slightly higher than that obtained in a large 
cohort of asymptomatic male BrS-patients from 4 of the largest centers cooperating in 
SABRUS (27.8% vs. 20.8%, P<0.001) (Table 3). However, in our female SABRUS-patients 
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the SCN5A mutation rate was markedly higher than in asymptomatic female BrS-
patients (47.6% vs. 26.8%, P<0.001) (Table 3). Therefore, the relatively higher mutation 
rates observed in our female cohort with AE would suggest that the presence of an 
SCN5A mutation could represent an important risk marker for AE in the female patient 
population and to a much lesser extent in male patients.  
Five (63%) of the 8 females of group B3 were SCN5A mutation carriers (Online Table 1). 
This could suggest that there might be additional value of genetic testing for deciding 
upon prophylactic ICD-implantation in females that should be assessed in prospective 
studies.  
Clinical implications.   
Arrhythmic risk stratification of BrS-patients is not an easy task in males and even more 
so in females. The present study suggests for the first time the possible predictive value 
of the presence of an SCN5A mutation in female patients that should be assessed 
prospectively.  
Study limitations.  
In addition to study limitations listed elsewhere
9,10
 it is worthwhile emphasizing that 
despite the relatively large female cohort patient (n=59), our results from genetic 
testing derived from only 42 (71%) female patients. In addition, we acknowledge the 
problematic comparison in the pediatric and elderly groups due to a small sample size, 
and conclusion drawing must be done carefully. 
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A history of sinus node dysfunction was found by the Pedro Brugada group to represent 
a significant predictor of AE.
15,16
 This parameter was not systematically assessed in our 
study. 
Conclusion 
Besides confirming previously known differences, this largest comparative study shows 
for the first time multiple important gender differences in BrS patients, especially the 
complex relationship between gender distribution and patient ethnicity with age at 
onset of AE as well as a possible worse prognosis associated with the presence of SCN5A 
mutation in females. It is important that all these factors will be taken into account in 
future studies on arrhythmic risk stratification in BrS. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15 
                                                           REFERENCES 
 
1. Mizusawa Y, Wilde AA. Brugada syndrome. Circ Arrhythm Electrophysiol. 2012;5:606-
616. 
2. Antzelevitch C, Yan GX, Ackerman MJ, et al. J-Wave syndromes expert consensus 
conference report: Emerging concepts and gaps in knowledge. J Arrhythm. 2016;32:315-
339. 
3. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with 
Brugada syndrome results from the FINGER Brugada Syndrome Registry. Circulation. 
2010;121:635–643. 
4. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defibrillator therapy in 
Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol. 2015;65:879-
888. 
5. Sacher F, Meregalli P, Veltmann C, et al. Are women with severely symptomatic 
Brugada syndrome different from men? J Cardiovasc Electrophysiol. 2008;19:1181-1185. 
6. Priori S, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome. 
Results of the PRELUDE registry. J Am Coll Cardiol 2012;59:37–45.  
7. Benito B, Sarkozy A, Mont L, Henkens S, Berruezo A, Tamborero D, Arzamendi D, 
Berne P, Brugada R, Brugada P, Brugada J. Gender differences in clinical manifestations 
of Brugada syndrome. J Am Coll Cardiol. 2008;52:1567-1673.  
8. Sieira J, Conte G, Ciconte G, et al. Clinical characterisation and long-term prognosis of 
women with Brugada syndrome. Heart. 2016;102:452-458.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16 
9. Milman A, Andorin A, Gourraud J-B, et al. Age of first arrhythmic event in Brugada 
syndrome: Data from the survey on arrhythmic events in Brugada syndrome (SABRUS) in 
678 patients. Age of first arrhythmic event in Brugada syndrome: Data from the SABRUS 
(Survey on arrhythmic events in Brugada syndrome) in 678 patients. Circ Arrhythm 
Electrophysiol 2017;10:e005222,DOI:10.1161/CIRCEP.117.005222.   
10. Milman A, Andorin A, Gourraud J-B, et al. Profile of patients with Brugada syndrome 
presenting with their first documented arrhythmic event: Data from the Survey on 
Arrhythmic Events in BRUgada Syndrome (SABRUS). Heart Rhythm. 2018;15:716-724. 
doi: 10.1016/j.hrthm.2018.01.014. Epub 2018 Jan 8. 
11. Priori SG, Wilde AA, Horie M, et al. Heart Rhythm Society; European Heart Rhythm 
Association; Asia Pacific Heart Rhythm Society. HRS/EHRA/APHRS expert consensus 
statement on the diagnosis and management of patients with inherited primary 
arrhythmia syndromes. Europace. 2013;15:1389-1406. 
12. Bezzina CR, Shimizu W, Yang P,  Koopmann TT, Tanck MW, Miyamoto Y, Kamakura 
S, Roden DM, Wilde AA. Common sodium channel promoter haplotype in Asian subjects 
underlies variability in cardiac conduction. Circulation. 2006;113:338–344.  
13. Royer A, van Veen TA, Le Bouter S, et al. Mouse model of SCN5A-linked hereditary 
Lenègre's disease: age-related conduction slowing and myocardial fibrosis. 
Circulation. 2005;111:1738-1746. 
14. Yamagata K, Horie M, Aiba T, et al. Genotype-phenotype correlation of SCN5A 
mutation for the clinical and electrocardiographic characteristics of probands with 
Brugada syndrome: A Japanese multicenter registry. Circulation. 2017;135:2255-2270.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 17 
15. Sieira J, Conte G, Ciconte G, et al. A score model to predict risk of events in patients 
with Brugada syndrome. Eur Heart J. 2017;38:1756-1763.  
16. Sieira J, Ciconte G, Conte G, et al. Asymptomatic Brugada syndrome: Clinical 
characterization and long-term prognosis. Circ Arrhythm Electrophysiol. 2015;8:1144-
1150.  
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 18 
Table 1. Patients characteristics according to gender.  
 
    Male  Female   P value 
Number of patients   619 59   
Patient Age at AE (year) Age range 0.27-84 0.36-84   
  All patients (n=678) 41.9±14.0 42.1±21.2 0.225 
  < 16 years (n=29)  19 (3) 10 (17) <0.001
 
  16-70 (n=639) 593 (96) 46 (78) <0.001
 
  >70 years (n=10) 7 (1) 3 (5) <0.05
 
Mode of AE documentation          
  Group A (n=426) 390 (63) 36 (61) 0.763 
  Group B (n=252) 229 (37) 23 (39) 
  Group B1 (n=112) 102 (45) 10 (43)  
  Group B2 (n=77) 72 (31) 5 (22) 0.482 
  Group B3 (n=63) 55 (24) 8 (35)  
  Subgroup B3a (n=33)        27 (49) 6 (75) 0.261 
  Subgroup B3b (n=30)        28 (51) 2 (25) 
Ethnicity         
  Caucasian (n=364)  312 (50) 52 (88) <0.001 
  Asian (n=270) 265 (43) 5 (8) 
  Other/Unknown (n=44)           42 (7) 2 (3) 
Proband Status     
 Proband (n=542) 496 (80) 46 (78) 0.121 
 Not Proband (n=88) 76 (12) 12 (20) 
 Unknown (48) 47 (8) 1 (2) 0.111 
Family history of SCD         
  Yes (n=145) 128 (21) 17 (29) 0.287 
  No (n=468) 427 (69) 41 (69) 
  Unknown (n=65) 64 (10) 1 (2) <0.05 
History of syncope         
  Yes (n=265) 237 (38) 28 (47) 0.168 
   No (n=413) 382 (62) 31 (53) 
Spontaneous type-1 BrS-ECG        
  Yes (n=451) 427 (69) 24 (41) <0.001 
  No (n=227) 192 (31) 35 (59) 
VF inducibility        
  EPS performed (n=400)              361 (58) 39 (66) 0.246 
  Inducible (n=253) 239 (66) 14 (36) <0.001 
  Not inducible (n=147) 122 (34) 25 (64) 
Presence of SCN5A mutation        
  Testing done (n=485)         443 (72) 42 (71) 0.825 
  SCN5A mutation (n=143) 123 (28) 20 (48) <0.01 
 No SCN5A mutation (n=342) 320 (72) 22 (52)  
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Abbreviations: n (%) unless otherwise indicated. 
 AE = arrhythmic event; BrS = Brugada syndrome; ECG = electrocardiogram; EPS = 
electrophysiologic study; Group A = cardiac arrest survivors; Group B = patients who received 
an appropriate shock from their ICD after prophylactic implantation; Group B1 =  Class IIa 
indication (11); Group B2 = Class IIb indication (11); Group B3 = neither Class IIa nor Class IIb; 
Subgroup B3a = no inducible VF at EPS; Subgroup B3b = EPS not performed; SCD = sudden 
cardiac death; VF = ventricular fibrillation. 
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Table 2. Comparison of the age at time of AE between males and females in 
regard to the mode of AE documentation, ethnicity and various clinical 
characteristics.  
 
2A. In all patients 
    Male Female P-value 
Number of patients   619  59    
Mean age at time of AE   41.9±14  42.1±21.2  0.255  
Mode of AE documentation  Group A 39.5±14 37.5±23.5 0.783 
  Group B 45.8±13.1 49.3±14.8 0.078 
Ethnicity 
Caucasian 41.2±15 41.9±21.4 0.222 
  
Asian 43.3±12.2 45±18.8 0.915 
Clinical characteristics Proband status 42±14 42.9±21.2 0.273 
  Family history of SCD 41.7±14 38.4±21.3 0.909 
  Prior history of syncope 41.3±15.2 45.2±19 0.061 
  Spontaneous type-1 BrS-ECG 41.8±14.3 42.2±25 0.246 
  Positive EPS 43.4±13 44.4±18.7 0.387 
  Presence of SCN5A mutation 38.4±15.8 33.7±24.7 0.643 
 
2B. In patients aged > 16 years old. 
    Male Female P-value 
Number of patients   600  49    
Mean age at time of AE   43±12.7  49.5±14.4  0.001  
Mode of AE documentation  
Group A 41±12.4 47.9±16.8 0.029 
  Group B 46.3±12.4 51.5±10.6 0.037 
Ethnicity Caucasian 43.1±12.9 49.6±13.8 0.002 
  
Asian 43.4±12.1 45±18.8 0.926 
Clinical characteristics Proband status 43±12.7 49.4±15.4 0.005 
  
Family history of SCD 42.6±13 48±13 0.120 
  Prior history of syncope 43.3±12.9 50±13.5 0.009 
  Spontaneous type-1 BrS-ECG 43.2±12.6 53.1±14.2 0.002 
  Positive EPS 43.8±12.5 47.8±14.5 0.185 
  Presence of SCN5A mutation 41.3±12.8 49.3±13.9 0.041 
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2C. In patients aged <16 years old. 
    Male Female P-value 
Number of patients   19  10  
Mean age at time of AE    6.2±4.9 5.8±6.2  0.636  
Mode of AE documentation  
Group A 5.8±5.3 6.3±6.4 0.978 
  Group B 8.3±0.6 1.1±0 0.500 
Ethnicity Caucasian 6.2±5.2 4.8±5.6 0.419 
  
Asian 9±0 NA NA 
Clinical characteristics Proband status 4.8±4.6 6.4±6.6 0.699 
  
Family history of SCD 6.7±5.7 7.3±7.5 0.857 
  Prior history of syncope 6.2±5.1 5.6±5.3 0.900 
  Spontaneous type-1 BrS-ECG 5.9±4.7 0.9±0.7 0.004 
  Positive EPS 2.1±1.2 0.8±0 0.667 
  Presence of SCN5A mutation 5.1±4.5 4.7±6.3 0.740 
 
Abbreviations: AE = arrhythmic event; BrS = Brugada syndrome; ECG = electrocardiogram; EPS = 
electrophysiologic study; Group A = cardiac arrest survivors; Group B = patients who received an 
appropriate shock from their ICD after prophylactic implantation; SCD = sudden cardiac death. 
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Table 3. Comparison of SCN5A mutation rates in SABRUS and a Registry of Asymptomatic 
BrS Subjects in respect to gender  
 
       
  Males Females  P 
 < 16 yrs 26/91 (28.6%) 34/110 (30.9%) 0.71 
Registry > 16 yrs  206/1025 (20.1%) 137/528 (25.9%) 0.0085 
 All ages 232/1116 (20.8%) 171/638 (26.8%) 0.004 
       
 < 16 yrs 10/15 (66.7%) 7/10 (70%) 0.86 
SABRUS > 16 yrs  113/428 (26.4%) 13/32 (40.6%) 0.082 
 All  ages 123/443 (27.8%) 20/42 (47.6%) 0.007 
       
 
The Registry data originated from the following 4 SABRUS centers: 
- L'Institut du Thorax, Service de Cardiologie, CHU de Nantes, Nantes, France 
(n=1104 sujects); 
-  Division of Cardiology, University of Torino, Torino, Italy (n=288 subjects);  
- Heart Rhythm Management Centre, UZ-VUB, Brussels, Belgium (n=205 subjects);  
- Pediatric Arrhythmias, Electrophysiology and Sudden Death Unit Cardiology 
Department, Hospital Sant Joan de Déu, Barcelona, Spain (n=157 subjects). 
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                                                                 Figures legends 
Figure 1.  Male to female (M/F) ratio of arrhythmic event (AE) in various age groups in the 
678 SABRUS patients (A) and in the 6441 patients of the Registry (B). The M/F ratio is 
indicated into the bars for each age group. The numbers above the bars indicate the absolute 
numbers of males and females, respectively, for each age group. In both SABRUS and the 
Registry, the M/F ratios were the highest in the 27-37 years age group. Note that the M/F 
ratio distribution is similar in both patient groups.   
Figure 2. Male to female (M/F) ratio of arrhythmic event (AE) by ethnicity in various age 
groups in the 678 SABRUS patients (A) and in the 6441 patients of the Registry (B). The 
M/F ratio is indicated into the bars for each age group.  In both SABRUS and the 
Registry, the M/F ratios were markedly greater in Asians than in Caucasians.  The 
greatest M/F ratios were observed for Asians in the 38-48 years old age group in 
SABRUS (n=90) and in the 27-37 years old age group in the Registry (n=86).  
Figure 3.  Gender comparison of the proportions of patients with a family history of 
sudden cardiac death (panel A), prior history of syncope (panel B), presence of a 
spontaneous type 1 Brugada-ECG pattern (panel C) and inducibility of ventricular 
fibrillation at electrophysiologic study (panel D). 
Figure 4.  SCN5A mutations rates in SABRUS according to gender in respect to patient 
age group at the time of AE occurrence.  Higher mutation rates were observed in 
females at all age groups with the highest figures (70% and 60%) observed in the 
pediatric and the 60-70 years age group, respectively. Of note the highest mutation rate 
in males (66.7%) was also found in the pediatric group. 
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